title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
AbbVie  ( ABBV )  Announces Appointment of New CEO Robert Michael,20240221T154300,https://www.zacks.com/stock/news/2229455/abbvie-abbv-announces-appointment-of-new-ceo-robert-michael,ABBV,0.714592,Somewhat-Bullish,0.343678
Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research,20230515T093200,https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html,ABBV,0.017394,Neutral,-0.017349
"Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study",20220802T122759,https://www.benzinga.com/general/biotech/22/08/28308082/biotech-daily-trial-setback-for-eliem-therapeutics-allarity-drops-work-on-cancer-monotherapies-ax,ABBV,0.157483,Neutral,0.079368
"Open-Angle Glaucoma Market Size and Share to Accelerate Substantially by 2032, Predicts DelveInsight | Key Companies in the Market - SPARC, AbbVie, Ocuphire, Santen, Glaukos, Ocular Therapeutix, VivaVision Biotech, MediPrint Ophthalmics",20231012T210100,https://www.prnewswire.com/news-releases/open-angle-glaucoma-market-size-and-share-to-accelerate-substantially-by-2032-predicts-delveinsight--key-companies-in-the-market---sparc-abbvie-ocuphire-santen-glaukos-ocular-therapeutix-vivavision-biotech-mediprint-ophth-301954523.html,ABBV,0.051276,Neutral,0.079668
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",20231122T220100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,ABBV,0.039505,Neutral,0.102193
"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More",20220414T133544,https://www.benzinga.com/general/biotech/22/04/26630399/the-daily-biotech-pulse-pfizer-biontech-covid-19-booster-data-in-kids-regenerons-covid-19-therapy,ABBV,0.08395,Neutral,0.011626
Tuniu  ( NASDAQ:TOUR )  Stock Rating Lowered by StockNews.com,20230218T081645,https://www.defenseworld.net/2023/02/18/tuniu-nasdaqtour-stock-rating-lowered-by-stocknews-com.html,ABBV,0.092927,Neutral,0.107507
Tuniu  ( NASDAQ:TOUR )  Stock Rating Lowered by StockNews.com,20220826T070646,https://reporter.am/2022/08/26/tuniu-nasdaqtour-stock-rating-lowered-by-stocknews-com.html,ABBV,0.149656,Neutral,0.135655
48 Stocks Moving In Friday's Mid-Day Session,20220429T162716,https://www.benzinga.com/news/22/04/26904587/48-stocks-moving-in-fridays-mid-day-session,ABBV,0.066011,Neutral,0.000443
70 Biggest Movers From Friday,20220502T094646,https://www.benzinga.com/news/22/05/26923653/70-biggest-movers-from-friday,ABBV,0.05261,Somewhat-Bearish,-0.321513
"Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In - Corbus Pharmaceuticals  ( NASDAQ:CRBP ) , AbbVie  ( NYSE:ABBV ) ",20240514T173240,https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38803783/will-pharma-and-healthcare-have-competitive-edge-in-cannabis-post-rescheduling-data,ABBV,0.088964,Neutral,-0.089544
Roche's  ( RHHBY )  Lunsumio Application Gets Priority Review,20220706T171700,https://www.zacks.com/stock/news/1948787/roches-rhhby-lunsumio-application-gets-priority-review,ABBV,0.048681,Neutral,0.000723
"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer Bio",20230719T210100,https://www.prnewswire.com/news-releases/hypertension-market-to-accelerate-positively-estimates-delveinsight--key-companies-active-in-the-market---novartis-bayer-merck-insmed-acceleron-abbvie-alnylam--apnimed-astrazeneca-gossamer-bio-301880558.html,ABBV,0.049577,Neutral,0.059691
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",20231004T210100,https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,ABBV,0.086948,Neutral,-0.051258
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,ABBV,0.02074,Neutral,-0.020974
MacroGenics  ( MGNX )  Q4 2023 Earnings Call Transcript,20240308T053017,https://www.fool.com/earnings/call-transcripts/2024/03/08/macrogenics-mgnx-q4-2023-earnings-call-transcript/,ABBV,0.012228,Neutral,0.073709
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,ABBV,0.020404,Neutral,-0.005463
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,20230626T210100,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,ABBV,0.020903,Neutral,0.064977
"I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022",20220830T100000,https://www.prnewswire.com/news-releases/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-six-months-ended-june-30-2022-301614531.html,ABBV,0.05035,Neutral,0.12269
"I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021",20220329T101000,https://www.prnewswire.com/news-releases/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-ended-december-31-2021-301512585.html,ABBV,0.027123,Neutral,0.05172
Molecular Partners AG  ( MOLN )  Q4 2021 Earnings Call Transcript,20220316T190029,https://www.fool.com/earnings/call-transcripts/2022/03/16/molecular-partners-ag-moln-q4-2021-earnings-call-t/,ABBV,0.011216,Bullish,0.523568
CoolSculpting® Elite Announces First Ever CoolMonth - Investing News Network,20230403T124033,https://investingnews.com/coolsculpting-r-elite-announces-first-ever-coolmonth/,ABBV,0.100518,Neutral,0.079514
Tissue Engineering Market is Expected to Reach $8.9 Billion | MarketsandMarkets™,20240122T123000,https://www.benzinga.com/pressreleases/24/01/g36713761/tissue-engineering-market-is-expected-to-reach-8-9-billion-marketsandmarkets,ABBV,0.03792,Neutral,-0.040123
"The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis",20241202T100000,https://www.zacks.com/stock/news/2377440/the-zacks-analyst-blog-highlights-roche-poseida-therapeutics-merck-astrazeneca-and-novartis,ABBV,0.094576,Neutral,-0.073236
"Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success",20241129T200000,https://www.zacks.com/stock/news/2377348/pharma-stock-roundup-rhhby-to-buy-pstx-mrk-azn-see-pipeline-success,ABBV,0.096477,Neutral,-0.073587
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",20230925T210100,https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,ABBV,0.037504,Neutral,0.029512
StockNews.com Initiates Coverage on Profire Energy  ( NASDAQ:PFIE ) ,20220826T092243,https://reporter.am/2022/08/26/stocknews-com-initiates-coverage-on-profire-energy-nasdaqpfie-2.html,ABBV,0.08183,Neutral,0.089365
Profire Energy  ( NASDAQ:PFIE )  Earns Hold Rating from Analysts at StockNews.com,20220720T053448,https://reporter.am/2022/07/20/profire-energy-nasdaqpfie-earns-hold-rating-from-analysts-at-stocknews-com.html,ABBV,0.070725,Neutral,0.079133
VAALCO Energy  ( NYSE:EGY )  Rating Lowered to Hold at StockNews.com,20230218T073641,https://www.defenseworld.net/2023/02/18/vaalco-energy-nyseegy-rating-lowered-to-hold-at-stocknews-com.html,ABBV,0.100729,Neutral,0.087764
5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why,20220630T212500,https://www.investors.com/research/nyse-stocks-to-watch-buy/,ABBV,0.165693,Neutral,-0.115878
GRI Bio  ( NASDAQ: GRI )  Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry,20230424T120500,https://www.globenewswire.com/news-release/2023/04/24/2652685/0/en/GRI-Bio-NASDAQ-GRI-Announces-Board-of-Director-Appointments-Adding-Leadership-and-Expertise-Spanning-a-Combined-75-Years-in-Both-Public-and-Private-Sectors-in-the-Life-Sciences-Ind.html,ABBV,0.025433,Neutral,0.047183
"Dow Jumps 700 Points; S&P 500 Rises Over 2% - Aehr Test Systems  ( NASDAQ:AEHR ) , ATAI Life Sciences  ( NASDAQ:ATAI ) ",20230106T194324,https://www.benzinga.com/news/earnings/23/01/30316154/dow-jumps-700-points-s-p-500-rises-over-2,ABBV,0.05257,Neutral,0.071651
"Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket - Alset  ( NASDAQ:AEI ) , ADC Therapeutics  ( NYSE:ADCT ) ",20221221T110213,https://www.benzinga.com/news/22/12/30157281/why-core-scientific-shares-are-trading-lower-by-around-32-here-are-26-stocks-moving-premarket,ABBV,0.056808,Neutral,-0.020169
Why Is Bio-Path Holdings Stock Soaring On Tuesday? - Cassava Sciences  ( NASDAQ:SAVA ) ,20241008T132713,https://www.benzinga.com/general/biotech/24/10/41228945/nano-cap-bio-path-takes-plunge-in-weight-loss-race-initiates-obesity-program-with-drug-candidate-,ABBV,0.240489,Neutral,0.0
Ultrapar Participações  ( NYSE:UGP )  Stock Rating Upgraded by StockNews.com,20230219T062242,https://www.etfdailynews.com/2023/02/19/ultrapar-participacoes-nyseugp-stock-rating-upgraded-by-stocknews-com/,ABBV,0.097062,Neutral,0.145793
Ultrapar Participações  ( NYSE:UGP )  Stock Rating Upgraded by StockNews.com,20230219T062241,https://www.defenseworld.net/2023/02/19/ultrapar-participacoes-nyseugp-stock-rating-upgraded-by-stocknews-com.html,ABBV,0.097062,Neutral,0.145793
StockNews.com Lowers MBIA  ( NYSE:MBI )  to Sell,20220826T075441,https://reporter.am/2022/08/26/stocknews-com-lowers-mbia-nysembi-to-sell.html,ABBV,0.101154,Neutral,0.099056
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight,20230821T210100,https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html,ABBV,0.048671,Neutral,0.037506
"Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and Company, Janssen, Merck, BioVie, Biogen, Vivoryon, Sage, Alnylam, BioXcel, EIP, Otsuka, Alector, Transposon",20230726T210100,https://www.prnewswire.com/news-releases/dementia-market-to-grow-rapidly-estimates-delveinsight--key-companies-active-in-the-market---pfizer-eli-lilly-and-company-janssen-merck-biovie-biogen-vivoryon-sage-alnylam-bioxcel-eip-otsuka-alector-transposon-301885979.html,ABBV,0.047607,Neutral,0.049275
"Stocks Handle Huge Earnings, Fed, Jobs Report: Weekly Review",20240202T171500,https://www.investors.com/news/stock-market-handles-huge-earnings-week-fed-powell-jobs-report-weekly-review/,ABBV,0.049835,Neutral,-0.136008
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline,20241216T144200,https://www.zacks.com/stock/news/2383942/abbv-to-acquire-nimble-therapeutics-to-strengthen-immunology-pipeline,ABBV,0.677342,Bullish,0.544626
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal,20241210T153900,https://www.zacks.com/stock/news/2381629/abbvies-recently-acquired-parkinsons-drug-meets-third-study-goal,ABBV,0.273399,Neutral,0.138801
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20241127T130000,https://www.benzinga.com/pressreleases/24/11/g42212288/cytomx-therapeutics-to-present-at-the-36th-annual-piper-sandler-healthcare-conference,ABBV,0.087824,Neutral,0.041182
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference,20241127T130000,https://www.globenewswire.com/news-release/2024/11/27/2988176/37704/en/CytomX-Therapeutics-to-Present-at-the-36th-Annual-Piper-Sandler-Healthcare-Conference.html,ABBV,0.10607,Neutral,0.047068
"CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",20241031T120000,https://www.benzinga.com/pressreleases/24/10/g41650384/cytomx-therapeutics-to-report-third-quarter-2024-financial-results-on-november-7-2024,ABBV,0.089462,Neutral,0.048799
"CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors",20240909T120000,https://www.globenewswire.com/news-release/2024/09/09/2942754/37704/en/CytomX-Therapeutics-Announces-First-Patient-Dosed-with-CX-801-a-Dually-Masked-Interferon-Alpha-2b-PROBODY-in-a-Phase-1-Study-in-Patients-with-Solid-Tumors.html,ABBV,0.039483,Neutral,0.047495
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference,20240618T120000,https://www.globenewswire.com/news-release/2024/06/18/2900339/37704/en/CytomX-Therapeutics-to-Present-at-the-H-C-Wainwright-2nd-Annual-Immune-Cell-Engager-Virtual-Conference.html,ABBV,0.109956,Neutral,0.055734
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240617T201500,https://www.benzinga.com/pressreleases/24/06/g39366109/cytomx-therapeutics-promotes-chris-ogden-to-chief-financial-officer,ABBV,0.034087,Neutral,0.04386
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer,20240617T201500,https://www.globenewswire.com/news-release/2024/06/17/2900015/37704/en/CytomX-Therapeutics-Promotes-Chris-Ogden-to-Chief-Financial-Officer.html,ABBV,0.036091,Neutral,0.046131
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference,20240522T200500,https://www.globenewswire.com/news-release/2024/05/22/2886834/37704/en/CytomX-Therapeutics-to-Present-at-the-Jefferies-Global-Healthcare-Conference.html,ABBV,0.113597,Neutral,0.056493
CytomX Therapeutics Announces New Employment Inducement Grants,20240516T201500,https://www.globenewswire.com/news-release/2024/05/16/2883880/37704/en/CytomX-Therapeutics-Announces-New-Employment-Inducement-Grants.html,ABBV,0.098255,Neutral,0.051259
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240508T201000,https://www.benzinga.com/pressreleases/24/05/g38712713/cytomx-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-update,ABBV,0.015392,Neutral,0.04007
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA®  ( pembrolizumab ) ,20240507T201500,https://www.globenewswire.com/news-release/2024/05/07/2877258/37704/en/CytomX-Therapeutics-Announces-Clinical-Collaboration-with-Merck-to-Evaluate-CX-801-in-Combination-with-KEYTRUDA-pembrolizumab.html,ABBV,0.032961,Neutral,0.046708
AbbVie  ( ABBV )  to Report Q1 Earnings: What's in the Cards?,20240422T165600,https://www.zacks.com/stock/news/2259539/abbvie-abbv-to-report-q1-earnings-whats-in-the-cards,ABBV,0.470606,Somewhat-Bullish,0.262532
AbbVie  ( ABBV )  Posts Encouraging Data From Lung Cancer Study,20231130T165600,https://www.zacks.com/stock/news/2191706/abbvie-abbv-posts-encouraging-data-from-lung-cancer-study,ABBV,0.453501,Neutral,0.089073
"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis",20230906T210100,https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html,ABBV,0.022494,Neutral,0.023078
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update,20230808T201500,https://www.globenewswire.com/news-release/2023/08/08/2721181/37704/en/CytomX-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,ABBV,0.035902,Neutral,0.043602
Why CytomX Therapeutics  ( CTMX )  Shares Are Falling Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230328T153514,https://www.benzinga.com/general/biotech/23/03/31531824/abbvie-walks-away-from-cytomx-partnership-but-garnering-attention-of-big-pharma-partners,ABBV,0.62523,Neutral,0.10564
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update,20230327T201500,https://www.globenewswire.com/news-release/2023/03/27/2635245/37704/en/CytomX-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,ABBV,0.047528,Neutral,0.055674
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",20230322T232333,https://www.benzinga.com/pressreleases/23/03/g31466980/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-27-2023,ABBV,0.172097,Neutral,-0.036731
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023",20230322T232300,https://www.globenewswire.com/news-release/2023/03/22/2632792/37704/en/CytomX-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-27-2023.html,ABBV,0.184598,Neutral,-0.041876
CytomX Therapeutics to Present at Upcoming March Investor Conferences - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230228T210500,https://www.benzinga.com/pressreleases/23/02/g31103016/cytomx-therapeutics-to-present-at-upcoming-march-investor-conferences,ABBV,0.165031,Neutral,-0.037087
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific  ( TCB )  Collaboration with Astellas,20230126T120000,https://www.globenewswire.com/news-release/2023/01/26/2595893/37704/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-Probody-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html,ABBV,0.068209,Neutral,-0.02641
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference,20230117T210500,https://www.benzinga.com/pressreleases/23/01/g30450762/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor-conferen,ABBV,0.157483,Neutral,-0.053591
AbbVie cuts earnings forecast due to milestone payments,20230106T235200,https://www.marketwatch.com/story/abbvie-cuts-earnings-forecast-due-to-milestone-payments-11673048665,ABBV,0.817578,Somewhat-Bullish,0.216647
CytomX  ( CTMX )  Up 55% on Strategic Partnership With Moderna,20230106T184600,https://www.zacks.com/stock/news/2036409/cytomx-ctmx-up-55-on-strategic-partnership-with-moderna,ABBV,0.381755,Neutral,0.074788
"CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics - CytomX Therapeutics  ( NASDAQ:CTMX ) , Moderna  ( NASDAQ:MRNA ) ",20230105T210500,https://www.benzinga.com/pressreleases/23/01/g30301606/cytomx-and-moderna-announce-strategic-research-collaboration-for-mrna-based-conditionally-activate,ABBV,0.04476,Neutral,-0.026954
"CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023",20221222T220000,https://www.globenewswire.com/news-release/2022/12/22/2578939/37704/en/CytomX-Therapeutics-to-Outline-2023-Company-Priorities-and-Provide-Pipeline-Update-on-January-5-2023.html,ABBV,0.17715,Neutral,-0.042279
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference,20221220T220000,https://www.globenewswire.com/news-release/2022/12/20/2577524/37704/en/CytomX-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,ABBV,0.163909,Neutral,-0.059659
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20221220T220000,https://www.benzinga.com/pressreleases/22/12/g30153373/cytomx-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference,ABBV,0.153961,Neutral,-0.054343
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine  ( CX-2009 )  in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20221207T213000,https://www.benzinga.com/pressreleases/22/12/g29999143/cytomx-therapeutics-to-present-phase-2-data-for-praluzatamab-ravtansine-cx-2009-in-patients-with-a,ABBV,0.120733,Neutral,-0.047412
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine  ( CX-2009 )  in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium,20221207T213000,https://www.globenewswire.com/news-release/2022/12/07/2569745/37704/en/CytomX-Therapeutics-to-Present-Phase-2-Data-for-Praluzatamab-Ravtansine-CX-2009-in-Patients-with-Advanced-Breast-Cancer-at-the-San-Antonio-Breast-Cancer-Symposium.html,ABBV,0.069596,Neutral,-0.041707
CytomX  ( CTMX )  Stock Surges on Oncology Deal With Regeneron,20221118T181800,https://www.zacks.com/stock/news/2020092/cytomx-ctmx-stock-surges-on-oncology-deal-with-regeneron,ABBV,0.325924,Neutral,-0.037741
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b  ( CX-801 )  at the SITC 2022 Annual Meeting,20221107T211500,https://www.globenewswire.com/news-release/2022/11/07/2550277/37704/en/CytomX-Therapeutics-to-Present-Preclinical-Data-for-Conditionally-Activated-Interferon-Alpha-2b-CX-801-at-the-SITC-2022-Annual-Meeting.html,ABBV,0.07031,Neutral,-0.043812
CytomX Therapeutics to Present at Upcoming November Investor Conferences,20221102T201500,https://www.globenewswire.com/news-release/2022/11/02/2547066/37704/en/CytomX-Therapeutics-to-Present-at-Upcoming-November-Investor-Conferences.html,ABBV,0.166743,Neutral,-0.06039
CytomX Therapeutics to Present at Upcoming November Investor Conferences - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20221102T201500,https://www.benzinga.com/pressreleases/22/11/g29532629/cytomx-therapeutics-to-present-at-upcoming-november-investor-conferences,ABBV,0.143415,Neutral,-0.052044
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249,20220912T120000,https://www.globenewswire.com/news-release/2022/09/12/2513952/37704/en/CytomX-Therapeutics-Announces-Phase-1-Data-Update-for-anti-CTLA-4-Probody-Therapeutic-BMS-986249.html,ABBV,0.076602,Neutral,-0.056691
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate  ( ADC )  Programs Including Next Generation EpCAM-Targeting CX-2051,20220907T220500,https://www.globenewswire.com/news-release/2022/09/07/2512047/37704/en/CytomX-Therapeutics-Presents-Overview-of-Conditionally-Activated-Antibody-Drug-Conjugate-ADC-Programs-Including-Next-Generation-EpCAM-Targeting-CX-2051.html,ABBV,0.059415,Neutral,-0.056235
CytomX Therapeutics  ( CTMX )  Q2 2022 Earnings Call Transcript,20220805T123040,https://www.fool.com/earnings/call-transcripts/2022/08/05/cytomx-therapeutics-ctmx-q2-2022-earnings-call-tra/,ABBV,0.034497,Neutral,0.011633
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update,20220804T201500,https://www.globenewswire.com/news-release/2022/08/04/2492842/37704/en/CytomX-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Business-Update.html,ABBV,0.098416,Neutral,0.001092
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences,20220803T120000,https://www.globenewswire.com/news-release/2022/08/03/2491316/37704/en/CytomX-Therapeutics-to-Present-at-Upcoming-Virtual-August-Investor-Conferences.html,ABBV,0.19117,Neutral,-0.088654
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer,20220706T200500,https://www.globenewswire.com/news-release/2022/07/06/2475436/37704/en/CytomX-Therapeutics-Announces-Phase-2-Results-for-Praluzatamab-Ravtansine-in-Breast-Cancer.html,ABBV,0.041545,Somewhat-Bullish,0.290945
CytomX Therapeutics  ( CTMX )  Q1 2022 Earnings Call Transcript,20220507T023041,https://www.fool.com/earnings/call-transcripts/2022/05/06/cytomx-therapeutics-ctmx-q1-2022-earnings-call-tra/,ABBV,0.021161,Somewhat-Bullish,0.229837
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update,20220505T201500,https://www.globenewswire.com/news-release/2022/05/05/2437387/37704/en/CytomX-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Provides-Business-Update.html,ABBV,0.101273,Somewhat-Bullish,0.179309
"CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022",20220428T120000,https://www.globenewswire.com/news-release/2022/04/28/2431297/37704/en/CytomX-Therapeutics-to-Report-First-Quarter-2022-Financial-Results-on-May-5-2022.html,ABBV,0.174398,Somewhat-Bullish,0.273357
"CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors",20220414T201500,https://www.benzinga.com/pressreleases/22/04/g26646216/cytomx-therapeutics-announces-retirement-of-john-a-scarlett-m-d-from-board-of-directors,ABBV,0.130748,Somewhat-Bullish,0.20252
"CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors",20220414T201500,https://www.globenewswire.com/news-release/2022/04/14/2423090/37704/en/CytomX-Therapeutics-Announces-Retirement-of-John-A-Scarlett-M-D-from-Board-of-Directors.html,ABBV,0.071209,Somewhat-Bullish,0.273357
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors,20220323T201500,https://www.benzinga.com/pressreleases/22/03/g26266130/cytomx-therapeutics-announces-retirement-of-frederick-w-gluck-from-board-of-directors,ABBV,0.123748,Somewhat-Bullish,0.20252
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors,20220323T201500,https://www.globenewswire.com/news-release/2022/03/23/2408989/37704/en/CytomX-Therapeutics-Announces-Retirement-of-Frederick-W-Gluck-from-Board-of-Directors.html,ABBV,0.137318,Somewhat-Bullish,0.273357
"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight",20231009T210100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html,ABBV,0.036338,Neutral,0.029364
Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Raised to Buy at StockNews.com,20220826T063441,https://reporter.am/2022/08/26/rigel-pharmaceuticals-nasdaqrigl-raised-to-buy-at-stocknews-com.html,ABBV,0.061631,Neutral,0.049335
"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech",20231016T210100,https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html,ABBV,0.051663,Neutral,-0.028928
"Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen",20230913T210100,https://www.prnewswire.com/news-releases/acute-lymphocytic-leukemia-market-to-accelerate-substantially-by-2032-assesses-delveinsight--key-companies-in-the-market---beam-pfizer-genentech-abbvie-fate-roche-ascentage-janssen-jazz-adc-kymera-syndax-immunogen-301925772.html,ABBV,0.043778,Neutral,0.034443
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20240711T213100,https://www.prnewswire.com/news-releases/molecular-glues-clinical-trial-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302194515.html,ABBV,0.049784,Neutral,0.031644
"Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors",20230620T134500,https://www.globenewswire.com/news-release/2023/06/20/2691253/0/en/Immix-Biopharma-Subsidiary-Nexcella-Appoints-Jeffrey-H-Cooper-former-Chief-Financial-Officer-of-BioMarin-to-Board-of-Directors.html,ABBV,0.073773,Neutral,-0.024154
"Reverse Goldilocks - why this bank is souring on stocks, for now",20240104T114700,https://www.marketwatch.com/story/reverse-goldilocks-why-this-bank-is-souring-on-stocks-for-now-a109f4ba,ABBV,0.09347,Neutral,0.093576
"Dow Rises 50 Points; Oxford Industries Shares Plunge - Torrid Holdings  ( NYSE:CURV ) , Allarity Therapeutics  ( NASDAQ:ALLR ) ",20230324T182821,https://www.benzinga.com/news/earnings/23/03/31496529/dow-rises-50-points-oxford-industries-shares-plunge,ABBV,0.065685,Neutral,0.0
"Crude Oil Down 1%; US Composite PMI Jumps In March - Torrid Holdings  ( NYSE:CURV ) , Allarity Therapeutics  ( NASDAQ:ALLR ) ",20230324T160406,https://www.benzinga.com/news/earnings/23/03/31494297/crude-oil-down-1-us-composite-pmi-jumps-in-march,ABBV,0.067347,Neutral,0.0
"Dow Down 150 Points; US Durable Goods Orders Drop In February - ADMA Biologics  ( NASDAQ:ADMA ) , Torrid Holdings  ( NYSE:CURV ) ",20230324T134745,https://www.benzinga.com/news/earnings/23/03/31491562/dow-down-150-points-us-durable-goods-orders-drop-in-february,ABBV,0.070105,Neutral,0.0
Calif. Pharmaceutical Companies AbbVie And Bristol Myers Lay Off 360-Here Are The Major U.S. Layoffs This Summer,20220917T171330,https://www.forbes.com/sites/brianbushard/2022/09/17/calif-pharmaceutical-companies-abbvie-and-bristol-myers-lay-off-360-here-are-the-major-us-layoffs-this-summer/,ABBV,0.027699,Neutral,-0.055408
